Dr. Shah on Biomarkers of Response to Immunotherapy in Gastric/GEJ Cancer

Manish A. Shah, MD, discusses biomarkers of response to immunotherapy gastric/gastroesophageal cancer.

Manish A. Shah, MD, Bartlett Family Associate Professor Gastrointestinal Oncology and associate professor of medicine at Weill Cornell Medical College, Cornell University, and associate attending physician at NewYork-Presbyterian Hospital, discusses biomarkers of response to immunotherapy in gastric/gastroesophageal junction (GEJ) cancer.

Mismatch repair deficiency (dMMR) status can inform whether a patient is likely to respond to immunotherapy, explains Shah.

Combined positive score (CPS) also serves as a marker of response to immunotherapy, says Shah.

CPS may indicate which patients will benefit from immunotherapy in the third-line setting, concludes Shah.

Related Videos
David Samuel Dicapua Siegel, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD